Pulmonary opacity (HP:0031457)
Opacity refers to any area that preferentially attenuates the x-ray beam and therefore appears more opaque than the surrounding area. It is a nonspecific term that does not indicate the size or pathologic nature of the abnormality.
Synonyms: No synonyms found for this term.
Comment: Increased pulmonary opacity is caused by a decrease in the ratio of gas to soft tissue (blood, lung parenchyma and stroma) in the lung.
Pubmed References: PMID:18195376
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | ABC transporters | 0.02007 | 0.1097 | 56.67 | 221.48 |
| 2 | Arrhythmogenic right ventricular cardiomyopathy | 0.03413 | 0.1097 | 32.75 | 110.63 |
| 3 | RNA degradation | 0.03500 | 0.1097 | 31.91 | 106.98 |
| 4 | TGF-beta signaling pathway | 0.04152 | 0.1097 | 26.74 | 85.09 |
| 5 | AGE-RAGE signaling pathway in diabetic complications | 0.04412 | 0.1097 | 25.12 | 78.38 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | positive regulation of chromosome organization (GO:2001252) | 0.00001884 | 0.002620 | 439.08 | 4776.89 |
| 2 | establishment of protein localization to telomere (GO:0070200) | 0.002248 | 0.02051 | 624.59 | 3808.55 |
| 3 | positive regulation of cardioblast differentiation (GO:0051891) | 0.002248 | 0.02051 | 624.59 | 3808.55 |
| 4 | lung morphogenesis (GO:0060425) | 0.002248 | 0.02051 | 624.59 | 3808.55 |
| 5 | tricuspid valve development (GO:0003175) | 0.002248 | 0.02051 | 624.59 | 3808.55 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | intronic transcription regulatory region sequence-specific DNA binding (GO:0001161) | 0.002248 | 0.01564 | 624.59 | 3808.55 |
| 2 | phosphatidylcholine flippase activity (GO:0140345) | 0.002248 | 0.01564 | 624.59 | 3808.55 |
| 3 | phosphatidylcholine transfer activity (GO:0120019) | 0.002248 | 0.01564 | 624.59 | 3808.55 |
| 4 | cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication (GO:0086083) | 0.002248 | 0.01564 | 624.59 | 3808.55 |
| 5 | RNA-directed DNA polymerase activity (GO:0003964) | 0.002697 | 0.01564 | 499.65 | 2955.69 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | alveolar lamellar body (GO:0097208) | 0.002697 | 0.04423 | 499.65 | 2955.69 |
| 2 | transferase complex, transferring phosphorus-containing groups (GO:0061695) | 0.004043 | 0.04423 | 312.23 | 1720.62 |
| 3 | spanning component of plasma membrane (GO:0044214) | 0.005836 | 0.04423 | 208.11 | 1070.48 |
| 4 | lamellar body (GO:0042599) | 0.005836 | 0.04423 | 208.11 | 1070.48 |
| 5 | spanning component of membrane (GO:0089717) | 0.008966 | 0.05230 | 131.39 | 619.44 |
Hub genes predicted as biomarkers & predicted approved FDA drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| TERT | OMACETAXINE MEPESUCCINATE |
| OBFC1 | ATENOLOL |
| RTEL1 | – |
| NKX2-1 | – |
| ABCA3 | – |
| DHX36 | – |
| DSP | ENALAPRIL |
| COL3A1 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, OCRIPLASMIN |
| BMPR2 | – |
